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Establishing cost-effectiveness of genetic tar-
geting of cancer therapies
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being 
evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Con-
structive Technology Assessment to help decision-making in an uncertain time of development.
Treatment for patients with cancer has shifted from administering broadly toxic drugs towards fine-tuning of therapies that are targeted 
to the personal characteristics of specific 
tumours. An example of this development 
is the possibility to base the decision of 
adjuvant systemic therapy for breast 
cancer on the results of a genomic prog-
nostic profile. The majority of early stage 
breast cancer patients, particularly with 
lymph node-negative disease (60–70%), 
have a fairly good 10-year overall survival 
with loco-regional treatment alone, with 
only 30–40% developing distant metasta-
sis [1]. Nevertheless, according to current 
guidelines, most lymph node-negative 
breast cancer patients are offered chemo-
therapy, causing an important percentage 
of overtreatment [2]. Overtreatment is 
associated with adverse effects and high 
costs, however, is understandable with 
the lack of a fully accurate method to select high risk patients 
needing chemotherapy. In 2002, researchers at The Nether-
lands Cancer Institute (NKI, Amsterdam, The Netherlands) 
identified a 70-gene prognosis signature (MammaPrintTM), 
using microarray analysis for lymph node-negative breast 
cancer patients [3]. Using the 70-gene signature, the selec-
tion of patients that will benefit most from adjuvant systemic 
treatment could be more accurate. The signature has been vali-
dated in four independent retrospective patient series [4-7]. A 
prospective feasibility study, the MicroarRAy PrognoSTics in 
Breast CancER (RASTER)-study was started in 2004 to inves-
tigate whether the collection of good quality tumour tissue 
from community hospitals and the analysis of the 70-gene sig-
nature was feasible [8].
Genomic knowledge leads to the introduction of new and 
increasingly personalised diagnostics and treatments, which 
lead to even more complex evaluation designs when follow-
ing common and accepted assessment practices. Thus, it would 
take at least 8–10 years to bring the 70-gene signature into clin-
ical practice, via the usual path of prospective trials. For these 
reasons, we chose to carry out a controlled introduction of the 
70-gene signature, supporting the RASTER-study with a com-
prehensive technology assessment, which takes technology 
dynamics into account, and decided 
to perform a Constructive Technology 
Assessment (CTA). CTA is based on the 
idea that during the course of technology 
development, choices are constantly being 
made about the form, the function, and the 
use of that technology [9]. This assess-
ment method is a possible answer to the 
economic evaluation challenges that new 
genomic technologies pose.
MINDACT-trial
After the feasibility study the MINDACT-
trial (Microarray In Node-negative Dis-
ease may Avoid ChemoTherapy) was 
designed. The MINDACT-trial will eval-
uate whether use of the 70-gene signature 
is associated with clinical benefit. It will 
provide findings on the exact prognos-
tic and predictive value of the 70-gene 
signature. The randomised controlled 
design allows a defined group of patients 
(age 18–70, node-negative, operable 
breast cancer) to have their treatment determined on the basis 
of either the 70-gene signature or standard practice guide-
lines (see Figure 1). Patients with discordant risk profiles 
will be randomised to chemotherapy treatment according 
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Figure 1: MINDACT-trial design
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to either the clinicopathological criteria (using the Adjuvant 
Online software [10]) or according to the 70-gene signature 
[11]. The trial plans to prospectively recruit 6,000 patients. 
A follow up of at least ten years will be required before the 
results are available [12]. The trial started recruiting in 2007 
and is expected to finish in 2012. The feasibility of the MIN-
DACT-trial has been proven [13], and the recruitment rate 
is as planned. The trial is currently ongoing in 10 European 
countries with 68 participating hospitals.
Constructive Technology Assessment
Coverage decisions regarding new technologies often have to 
be made at a time when the data on most relevant variables and 
adequate comparisons are not available yet from high-quality 
studies. Especially when the promising new technology is in its 
early development phase and certain stakeholders find reason 
to speed up implementation in clinical practice, health policy 
challenges arise. Health Technology Assesment (HTA) is 
widely adopted to help to manage the introduction and appro-
priate use of new technologies [14]. However, a HTA generally 
starts after the technology is stabilised and proved to be valid in 
clinical trials. During this time many changes in available treat-
ments can occur, which results in a HTA subsequently answer-
ing, at least partly, outdated questions [15]. The CTA is related 
to a HTA, which predominantly implies a cost-effectiveness 
analysis (CEA) or economic evaluation. CTA also takes tech-
nology dynamics into account and has developed from just 
assessing the impact of a new technology to the analysis of 
design, development, implementation and interaction of that 
new technology with its environment. Only a few publications 
are available describing the application of CTA in health care 
[15-17]. The aspects studied in this CTA on the 70-gene signa-
ture so far were: patient-related aspects (understanding of the 
70-gene signature and psychological impact), organisational 
efficiency (logistics and team functioning) and diffusion sce-
narios [17]. After the results of the controlled introduction trial 
were known [8], in The Netherlands a discussion was started 
as to whether Coverage with Evidence Development (CED) 
would be appropriate. CED represents a specific approach to 
coverage for promising technologies for which the evidence is 
uncertain yet [14], see Figure 2.
For this purpose, first a ‘conventional’ CEA was conducted. 
A Markov decision model was used to simulate the 10-year 
costs and outcomes (survival and quality-adjusted life years 
(QALYs)) based on a pooled database of three retrospective 
validation series. When deciding upon the cost-effectiveness of 
the prognostic tests, the 70-gene signature has a high potential 
to improve QALY and has the highest probability of being 
cost-effective.
Scenarios
Scenario drafting can be used as a tool in forecasting of new, 
still dynamic technologies. They are commonly applied in 
industry to anticipate on future development and diffusion of 
their products. Scenarios can be used to monitor the imple-
mentation process through the various diffusion phases and 
can support and identify the need for evaluation or even 
interfere through formal decision-making. In the case of the 
70-gene signature, the scenarios were written using the time-
line of diffusion phases as described by Rogers’ theory, 2003 
[18], see Figure 3. These phases reflect the degree of spread-
ing throughout the (medical) society. In the CTA-study, we 
applied scenario drafting in the case of the 70-gene signature. 
In the innovation phase, the prognosis signature technique was 
developed and the first organisations adopted (introduced) 
the technology in their daily practice. The first scenario was 
written before the prognosis signature was introduced in The 
Netherlands (mid-2004). The early adoption phase describes 
the implementation in 10–15 hospitals. The second, revised 
scenario was drafted based on the first experiences in the 
feasibility study (RASTER) in The Netherlands (mid-2006). 
The early majority phase describes the implementation in a 
gradually increasing number of hospitals and is ongoing. The 
70-gene signature has now been implemented in 25 hospitals 
in Europe. The third scenario was written at the beginning of 
the MINDACT trial (mid-2008), in the late early minority/
early majority phase. The third draft was written with pro-
fessional feedback. We designed questionnaires which were 
sent to 100 European breast cancer experts and organised 
a consensus workshop in Bordeaux, France. The question-
naires and consensus workshop looked at six patient cases 
to investigate the compliance with the prognosis profile and 
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ten different alternatives for the third scenario. The result of 
the consensus workshop was several probabilities (% of like-
liness to happen within the coming 10 years) for the ten dif-
ferent scenarios, see Figure 4.
Dynamic economic evaluation
The scenarios drafted on the subsequent phases of diffusion 
reflect possible ‘future worlds’ of the use of the 70-gene 
signature. Probabilistic decision modelling will be used to esti-
mate the cost-effectiveness of the 70-gene signature in these 
worlds, which may alter as time progresses and more infor-
mation becomes available. The various alternatives, barriers or 
facilitators that influence the diffusion of the 70-gene signature 
will be incorporated into the model as stochastic parameters. 
Parameters will be updated as soon as new information becomes 
available. At each moment in time, the decision to adopt or 
reject the new technology based on existing knowledge, and the 
decision whether more evidence is required can be informed by 
the results of the model [19]. Cost-effectiveness Acceptability 
Curves will reflect the degree of decision uncertainty and value 
of information (VOI) analyses implies whether additional 
evidence to further inform the decision is worth gathering, and 
what kind of information is of the greatest value [20]. VOI 
is the amount a decision maker would be willing to pay for 
information prior to making a decision. Finally, the integrated 
scenarios and VOI analysis reveals factors that warrant inter-
vention in the implementation process in case of the 70-gene 
signature [21].
Conclusion
Establishing the cost-effectiveness of genetic targeting of 
cancer therapies is increasingly desirable in an early stage 
when ‘traditional’ prospective randomised controlled data 
are not within reach. In the MINDACT-trial that would take 
another 8–10 years and future technologies with further person-
alised differentiation might even lead to conclusions that more 
qualitative trials will be conducted. However, the challenge 
is still to inform policy makers about possible advantages or 
disadvantages and, ultimately, to aid a decision on usage and 
coverage. A CTA evaluates a new technology in an early and 
unstable stage of development. Scenarios help to monitor the 
controlled introduction process and even can assist in antici-
pating on future developments. Dynamic economic evaluation 
can support the decision-making, by taking the several sce-
narios per diffusion phase into account in a decision model. 
We expect that these methods will prove valuable in combi-
nation with more ‘traditional’ cost-effectiveness analysis 
approaches.
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